** Shares in Formycon FYB.DE rise around 8% after it said it was developing its FYB208 drug as a biosimilar candidate for the immunological drug Dupixent

** The anti-inflammatory drug Dupixent is made by the U.S. drugmaker Regeneron Pharmaceuticals REGN.O in partnership with Sanofi SASY.PA

** Formicon says preclinical milestone technical proof of similarity (TPoS) demonstrates high analytical comparability of FYB208 to reference drug

** The stock is at the top of German small-cap index .SDAXI

(Reporting by Amir Orusov)

((Amir.orusov@thomsonreuters.com))